Roche Strengthens CNS Pipeline with reMYND Alliance
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 8 (Table of Contents)
Published: 18 Oct-2010
DOI: 10.3833/pdr.v2010.i8.1388 ISSN: 1756-7874
Section: Joint Venture
Fulltext:
Abstract
Roche has signed a drug development deal with the Belgian company reMYND to boost its early-stage pipeline for Alzheimer’s disease and Parkinson’s disease with potential disease-modifying therapies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS